Broncus Holding Corp
HKEX:2216
Net Margin
Broncus Holding Corp
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
CN |
B
|
Broncus Holding Corp
HKEX:2216
|
1.4B HKD |
-188%
|
|
US |
![]() |
Abbott Laboratories
NYSE:ABT
|
220.2B USD |
32%
|
|
US |
![]() |
Intuitive Surgical Inc
NASDAQ:ISRG
|
177.7B USD |
29%
|
|
US |
![]() |
Boston Scientific Corp
NYSE:BSX
|
157B USD |
14%
|
|
US |
![]() |
Stryker Corp
NYSE:SYK
|
154.2B USD |
12%
|
|
IE |
![]() |
Medtronic PLC
NYSE:MDT
|
119.1B USD |
14%
|
|
DE |
![]() |
Siemens Healthineers AG
XETRA:SHL
|
53.8B EUR |
9%
|
|
US |
![]() |
Becton Dickinson and Co
NYSE:BDX
|
53.1B USD |
7%
|
|
US |
![]() |
Edwards Lifesciences Corp
NYSE:EW
|
46.9B USD |
73%
|
|
US |
![]() |
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.6B USD |
23%
|
|
US |
![]() |
Resmed Inc
NYSE:RMD
|
40.4B USD |
26%
|
Broncus Holding Corp
Glance View
Broncus Holding Corp. engages in provision of interventional diagnosis and therapeutics solutions. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2021-09-24. The firm's business includes providing diagnostic solutions, lung cancer treatment solutions, chronic obstructive pulmonary disease solutions and navigation platforms. The diagnostic solutions pruducts include FleXNeedle, ATV Sheath, ATV Balloon and others. The lung cancer treatment solutions products include InterVapor for lung cancer, H-Marker and others. The chronic obstructive pulmonary disease (COPD) solutions products include InterVapor for COPD and TLD Ablation System. The navigation platform products include Lungpoint, Lungpro, New Generation Navigation Platform and others.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Broncus Holding Corp's most recent financial statements, the company has Net Margin of -188.2%.